FDA panel endorses controversial blood test

A U.S. FDA advisory panel approved the Galleri multi-cancer early detection blood test, developed by GRAIL, for screening adults aged 50 and older. The test analyzes DNA fragments in the bloodstream to detect multiple types of cancer at early stages, with positive results requiring further diagnostic procedures. While the panel supported its safety and effectiveness, critics note limitations and concerns about overdiagnosis. The FDA's final decision is expected in the coming months.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل